Myriad Genetics Inc(MYGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:21 AM ET (Korea 9/11 20:21)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.2 | Insider Own | 7.09% | Shs Outstand | 95.6M | Perf Week | 4.02% |
| Market Cap | 0.32B | Forward P/E | - | EPS next Y | 21.98% | Insider Trans | -0.11% | Shs Float | 88.9M | Perf Month | 4.35% |
| Enterprise Value | 0.42B | PEG | - | EPS next Q | -0.21 | Inst Own | 93.53% | Short Float | 8.65% | Perf Quarter | -24.15% |
| Income | -0.11B | P/S | 0.4 | EPS this Y | -1324.42% | Inst Trans | -4.09% | Short Ratio | 4.22 | Perf Half Y | -33.6% |
| Sales | 0.81B | P/B | 1.06 | EPS next 5Y | - | ROA | -17.11% | Short Interest | 7.68M | Perf YTD | -45.37% |
| Book/sh | 3.18 | P/C | 2.79 | EPS past 3/5Y | -41.67% -8.03% | ROE | -32.54% | 52W High | -60.88% ($8.59) | Perf Year | -51.3% |
| Cash/sh | 1.2 | P/FCF | - | Sales past 3/5Y | 6.72% 5.24% | ROIC | -22.2% | 52W Low | 22.63% ($2.74) | Perf 3Y | -78.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 72.02% | Gross Margin | 65.1% | Volatility(W/M) | 4.08% 5.28% | Perf 5Y | -89.89% |
| Dividend TTM | - | EV/Sales | 0.52 | Sales Y/Y TTM | -3.16% | Oper. Margin | -11.22% | ATR (14) | 0.22 | Perf 10Y | -83.45% |
| Dividend Ex-Date | - | Quick Ratio | 1.98 | EPS Q/Q | 87.25% | Profit Margin | -13.96% | RSI (14) | 46.41 | Recom | 3.3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.21 | Sales Q/Q | -10.51% | SMA20 | 6.31% ($3.16) | Beta | 1.69 | Target Price | $3.37 |
| Payout | - | Debt/Eq | 0.69 | Earnings | 2026/7/30 | SMA50 | -21.42% ($4.28) | Rel Volume | 2.16 | Prev Close | $3.19 |
| Employees | 2700 | LT Debt/Eq | 0.67 | EPS/Sales Surpr. | -332.53% -7.44% | SMA200 | -32.96% ($5.01) | Avg Volume(3M) | 1.82M | Price | $3.36 |
| IPO | 1995/10/6 | Option/Short | Yes/Yes | Trades | 9441 | Volume | 3,939,538 | Change | 5.33% |
Company
MYGN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A US-based precision diagnostics company specializing in hereditary cancer testing and molecular diagnostics. As a pioneer in gene-based cancer diagnostic testing, it offers a molecular diagnostics portfolio that includes hereditary cancer risk testing (MyRisk), mental health drug response testing (GeneSight), and prenatal testing, and operates across the oncology, women's health, and mental health segments.
Over the past 1 year, on the lower side
61% below its 1-year high.
MYGN has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -1324.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -79.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 93.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
QQQS 0.00%
GNOM 0.00%
FSCC 0.00%
HAPS 0.00%
PSCH 0.00%It ranks #4 in the industry
Based on market cap of $321M.
MYGN $321M PER -
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is MYGN?
MYGN belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of MYGN?
The market cap of MYGN is approximately $321M, ranking 3,646 within its sector.
What is the 52-week high and low for MYGN?
MYGN has recorded a 52-week high of $8.59 and a low of $2.74.
